


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on November 13, 2003

Kelly L. McDow-Dunham 43,787  
Name of Attorney/Agent Registration No.  
Signature of Attorney or Agent



P&G Case P137

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :  
Davenport et al. : Confirmation No.  
Serial No. 10/617,629 : Group Art Unit  
Filed July 11, 2003 : Examiner

For Synergistic Effect Of Diet And Human Interaction On The Behavior Of Dogs

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ **37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)**

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☒ **37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ **37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. ☐ **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case).** This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

☐ (1) (For use with applications filed prior to or on June 30, 2003.) Copies of the cited documents are enclosed.

OR

☐ (2) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

☐ (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. \_\_\_\_, U.S. Patent Application Serial No. \_\_, filed \_\_. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR


☐ (4) Copies of all said documents, except Cite Numbers \_\_\_\_, were submitted and considered in parent application U.S. Patent Application Serial No. \_\_\_\_, filed \_\_\_\_\_. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☐ (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,

By 

Kelly L. McDow-Dunham  
Attorney or Agent for Applicant(s)  
Registration No. 43,787  
(513)622-0159

Date: November 13, 2003  
Customer No. 27752  
(IDS.doc) (Last Revised 10/10/03)

**CO-PENDING U.S. APPLICATIONS**

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) must be sent with the IDS (see 37 CFR 1.98(a)(2)(iii))

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
-------------------------	----------------------	--------------------	--------------------

[Only applications that remain pending at the time of submitting this IDS should be listed here. For applications in which patents have issued, the granted patents should be listed on Form PTO/SB08.]

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a currently valid control number.</p> <p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p> <p><b>Stamp:</b> OIPE 3C/25 NOV 17 2003</p> <p>SHEET 1 of 3</p>		<p><b>COMPLETE IF KNOWN</b></p> <table border="1"> <tr> <td>Application Number</td> <td>10/617629</td> </tr> <tr> <td>Confirmation Number</td> <td></td> </tr> <tr> <td>Filing Date</td> <td>July 11, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Davenport et al.</td> </tr> <tr> <td>Group Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>P137</td> </tr> </table>		Application Number	10/617629	Confirmation Number		Filing Date	July 11, 2003	First Named Inventor	Davenport et al.	Group Art Unit		Examiner Name		Attorney Docket Number	P137
Application Number	10/617629																
Confirmation Number																	
Filing Date	July 11, 2003																
First Named Inventor	Davenport et al.																
Group Art Unit																	
Examiner Name																	
Attorney Docket Number	P137																

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENT								
EXAMINER INITIALS*	Cite No. <sup>1</sup>	Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
EXAMINER					DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: C mmissi ner f r Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [ + ]

PTO/SB08B (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p> <p>SHEET 2 of 3</p>	<b>COMPLETE IF KNOWN</b>	
	Application Number	10/617629
	Confirmation Number	
	Filing Date	July 11, 2003
	First Named Inventor	Davenport et al.
	Group Art Unit	
	Examiner Name	
Attorney Docket Number	P137o	

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	1	MOULTON, C." The role of animal shelters in controlling pet overpopulation", J. Am. Vet Med Assoc 198(&): 1172-1176 1991	
	2	HENNESSY, "Plasma cortisol levels of dogs at a county animal shelter", Physiol Behav 620: 485-490 1997	
	3	FOX, "Environmental factors influencing stereotyped and allelomimetic behavior in animals" Laboratory Animal Care, Vol. 15, No. 5 1965	
	4	LUESCHER ET AL., "Stereotypic or obsessive-compulsive disorders in dogs and cats", Veterinary Clinics of North America: Small Animal Practice - Vol. 21, No. 2, March 1991	
	5	MERTENS ET AL., "Effects of Group and Individual Housing on the behavior of kenneled dogs in animal shelters", Anthrozoos, Vol. IX, No. 1 - 1996	
	6	THOMPSON, "Whirling behavior in dogs as related to early experience", Science 123:939 1956	
	7	PATRONEK ET AL., "Risk factors for relinquishment of dogs to an animal shelter", J. Am Vet Med Assoc, Vol. 209, No. 3, 8/1/1996	
	8	ALMAN ET AL., "Human and animal factors related to the relinquishment of dogs and cats in 12 selected animal shelters in the United States", Journal of Applied Animal Welfare Science, 1(3), 207-226, 1998	
	9	BALLARINI, G., "Animal psychodietetics", Journal of Small Animal Practice (1990)31, 523-532	
	10	DODMAN ET AL., "Effect of dietary protein content on behavior in dogs", J Am Vet Med Assoc, Vol. 208(3): 376-379 1996	
	11	DENAPOLI ET AL., "Effect of dietary protein content and tryptophan supplementation on dominance aggression, territorial aggression, and hyperactivity in dogs", J Am Vet Med Assoc, Vol. 217(4): 504-508 2000	
	12	BEERDA ET AL., "Behavioural, saliva cortisol and heart rate responses to different types of stimuli in dogs", Applied Animal Behaviour Science 58 (1998) 365-381	
	13	COOVER ET AL., "Plasma corticosterone increases produced by extinction of operant behavior in rats", Physiology and Behavior, Vol. 6, pp 261-263, 1971	
	14	FRIEDMAN ET AL., "Adrenocortical response to novelty and noxious stimulation", Neuroendocrinology 2: 209-212 (1967)	
	15	HANSON ET AL., "The effects of control over high intensity noise on plasma cortisol levels in rhesus monkeys", Behavioral Biology 16, 333-340 (1996) Abstract No. 52317	
	16	HENNESSY, M.B., "Hypothalamic-pituitary-adrenal responses to brief social separation", Beuroscience and Biobehavioral Reviews, Vol. 21, No. 1 pp. 11-29, 1997	
	17	MUIR ET AL., "Corticosterone and prolactin responses to predictable and unpredictable novelty stress in rats", Physiology & Behavior, Vol. 37, pp 285-288, 1986	
	18	TUBER ET AL., "Behavioral and glucocorticoid responses of adult domestic dogs (canis familiaris) to companionship and social separation", Journal of Comparative Psychology, 1996, Vol. 110 No. 1, 103-108	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: C mmlssi ner f r Pat nts, P.O. B x 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [ + ]

PTO/SB08B (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>COMPLETE IF KNOWN</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	10/617629
		Confirmation Number	
		Filing Date	July 11, 2003
		First Named Inventor	Davenport et al.
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	P137o

SHEET 3 of 3

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	19	TUBER ET AL., "Dogs in animal shelters: problems, suggestions and needed expertise", Psychological Science, Vol. 10, No. 5, September 1999	
	20	HENNESSY ET AL., "Influence of male and female petters on plasma cortisol and behaviour: can human interaction reduce the stress of dogs in a public animal shelter", Applied Animal Behaviour Science 61 (1998) 63-77	
	21	VOITH, V. L., "Applied animal behavior for the veterinary practitioner, Applied Animal Behavior For The Veterinary Pract 47 <sup>th</sup> Annual Meeting: 1980	
	22	MARDER, A., "Do-it-yourself sit-stay", Readings in Companion Animal Behavior – Veterinary Bookchapter: 59-60	
	23	VOITH, V.L., "Teaching sit-stay", Clinical Animal Behavior, 1982 317-320	
	24	VOITH, V.L., "Teaching the down-stay", Clinical Animal Behavior, 1982	
	25	HENNESSY, ET AL., "Effects of program of human interaction and alterations in diet composition on activity of the hypothalamic-pituitary-adrenal axis in dogs housed in a public animal shelter", J. Am Vet Med Assoc, Vol. 221(1): 65-71, July 1, 2002	
	26	HENNESSY ET AL., "Exploring human interaction and diet effects on the behavior of dogs in a public animal shelter", Journal of Applied Animal Welfare Science, 5(4), 253-273, 2002	
	28	RILEY ET AL., "Psychoneuroimmunologic factors in neoplasia: studies in animals", Psychoneuroimmunology, 1981	
	29	DAVIDSON ET AL., "Feedback regulation of adrenocorticotropin secretion in 'basal' and 'stress' conditions: acute and chronic effects of intrahypothalamic corticoid implantation", Endocrinology 82, Vol. 82: 655-663 1968	
	30	DE BOER ET AL., "Plasma Catecholamine and corticosterone responses to predictable and unpredictable noise stress in rats", Physiology & Behavior, Vol. 45, pp. 789-795	